Taken together, these findings demonstrate that CMV inhibition can attenuate androgen signaling in CRPC and imply that CMV inhibition may have additive effects to androgen receptor‐targeting pharmaceutical compounds in CMV+ prostate cancer. This evidence concerns the gene AR and prostate cancer.